These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 9673281)

  • 1. Passive immunization with antibodies against three distinct epitopes on Plasmodium yoelii merozoite surface protein 1 suppresses parasitemia.
    Spencer Valero LM; Ogun SA; Fleck SL; Ling IT; Scott-Finnigan TJ; Blackman MJ; Holder AA
    Infect Immun; 1998 Aug; 66(8):3925-30. PubMed ID: 9673281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppressive and additive effects in protection mediated by combinations of monoclonal antibodies specific for merozoite surface protein 1 of Plasmodium yoelii.
    Eslava I; Payares G; Pernia BM; Holder AA; Spencer LM
    Malar J; 2010 Feb; 9():46. PubMed ID: 20146804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced protection against malaria by a chimeric merozoite surface protein vaccine.
    Shi Q; Lynch MM; Romero M; Burns JM
    Infect Immun; 2007 Mar; 75(3):1349-58. PubMed ID: 17158895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge.
    Rénia L; Ling IT; Marussig M; Miltgen F; Holder AA; Mazier D
    Infect Immun; 1997 Nov; 65(11):4419-23. PubMed ID: 9353014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration in host cell tropism limits the efficacy of immunization with a surface protein of malaria merozoites.
    Shi Q; Cernetich A; Daly TM; Galvan G; Vaidya AB; Bergman LW; Burns JM
    Infect Immun; 2005 Oct; 73(10):6363-71. PubMed ID: 16177307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice.
    Daly TM; Long CA
    Infect Immun; 1993 Jun; 61(6):2462-7. PubMed ID: 8363656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria.
    Chang SP; Case SE; Gosnell WL; Hashimoto A; Kramer KJ; Tam LQ; Hashiro CQ; Nikaido CM; Gibson HL; Lee-Ng CT; Barr PJ; Yokota BT; Hut GS
    Infect Immun; 1996 Jan; 64(1):253-61. PubMed ID: 8557348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral immunization with a combination of Plasmodium yoelii merozoite surface proteins 1 and 4/5 enhances protection against lethal malaria challenge.
    Wang L; Goschnick MW; Coppel RL
    Infect Immun; 2004 Oct; 72(10):6172-5. PubMed ID: 15385527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the protective efficacy of yeast-derived and Escherichia coli-derived recombinant merozoite surface protein 4/5 against lethal challenge by Plasmodium yoelii.
    Kedzierski L; Black CG; Stowers AW; Goschnick MW; Kaslow DC; Coppel RL
    Vaccine; 2001 Sep; 19(32):4661-8. PubMed ID: 11535314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combined epidermal growth factor-like modules of Plasmodium yoelii Merozoite Surface Protein-1 are required for a protective immune response to the parasite.
    Ling IT; Ogun SA; Holder AA
    Parasite Immunol; 1995 Aug; 17(8):425-33. PubMed ID: 7501423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria.
    Daly TM; Long CA
    J Immunol; 1995 Jul; 155(1):236-43. PubMed ID: 7602100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A protective monoclonal antibody recognizes an epitope in the carboxyl-terminal cysteine-rich domain in the precursor of the major merozoite surface antigen of the rodent malarial parasite, Plasmodium yoelii.
    Burns JM; Majarian WR; Young JF; Daly TM; Long CA
    J Immunol; 1989 Oct; 143(8):2670-6. PubMed ID: 2477452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasmodium: immunization with carboxyl-terminal regions of MSP-1 protects against homologous but not heterologous blood-stage parasite challenge.
    Rotman HL; Daly TM; Long CA
    Exp Parasitol; 1999 Jan; 91(1):78-85. PubMed ID: 9920045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective immune responses to the 42-kilodalton (kDa) region of Plasmodium yoelii merozoite surface protein 1 are induced by the C-terminal 19-kDa region but not by the adjacent 33-kDa region.
    Ahlborg N; Ling IT; Howard W; Holder AA; Riley EM
    Infect Immun; 2002 Feb; 70(2):820-5. PubMed ID: 11796616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challenge.
    Kedzierski L; Black CG; Coppel RL
    Infect Immun; 2000 Oct; 68(10):6034-7. PubMed ID: 10992516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigenic and sequence diversity at the C-terminus of the merozoite surface protein-1 from rodent malaria isolates, and the binding of protective monoclonal antibodies.
    Benjamin PA; Ling IT; Clottey G; Valero LM; Ogun SA; Fleck SL; Walliker D; Morgan WD; Birdsall B; Feeney J; Holder AA
    Mol Biochem Parasitol; 1999 Nov; 104(2):147-56. PubMed ID: 10593171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Passive transfer of Plasmodium falciparum MSP-2 pseudopeptide-induced antibodies efficiently controlled parasitemia in Plasmodium berghei-infected mice.
    Martínez PA; Yandar N; Lesmes LP; Forero M; Pérez-Leal O; Patarroyo ME; Lozano JM
    Peptides; 2009 Feb; 30(2):330-42. PubMed ID: 19071172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection.
    Narum DL; Ogun SA; Thomas AW; Holder AA
    Infect Immun; 2000 May; 68(5):2899-906. PubMed ID: 10768987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of protection induced by immunization with recombinant proteins from different regions of merozoite surface protein 1 of Plasmodium yoelii.
    Tian JH; Kumar S; Kaslow DC; Miller LH
    Infect Immun; 1997 Aug; 65(8):3032-6. PubMed ID: 9234750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection.
    Alaro JR; Lynch MM; Burns JM
    Vaccine; 2010 Oct; 28(42):6876-84. PubMed ID: 20709001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.